The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes

Mikkel Jürgens, Morten Schou, Philip Hasbak, Andreas Kjaer, Emil Wolsk, Bo Zerahn, Niels H Brandt-Jacobsen, Peter Gaede, Peter Rossing, Jens Oscar Faber, Silvio E. Inzucchi, F. Gustafsson, Caroline Kistorp*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

AIMS: To investigate the effects of empagliflozin on measured glomerular filtration rate (mGFR), estimated plasma volume (PV) and estimated extracellular volume (ECV) in a cohort of patients with type 2 diabetes (T2D) and high risk of cardiovascular events.

MATERIALS AND METHODS: In this prespecified substudy of the randomized, placebo-controlled SIMPLE trial, patients with T2D at high risk of cardiovascular events were allocated to either empagliflozin 25 mg or placebo once daily for 13 weeks. The prespecified outcome was between-group change in mGFR, measured by the 51 Cr-EDTA method after 13 weeks; changes in estimated PV and estimated ECV were included.

RESULTS: From April 4, 2017 to May 11, 2020, 91 participants were randomized. Of these, 45 patients from the empagliflozin group and 45 patients from the placebo group were included in the intention-to-treat analysis. Treatment with empagliflozin reduced mGFR by -7.9 mL/min (95% confidence interval [CI] -11.1 to -4.7; P < 0.001), estimated ECV by -192.5 mL (95% CI -318.0 to -66.9; P = 0.003) and estimated PV by -128.9 mL (95% CI -218.0 to 39.8; P = 0.005) at Week 13.

CONCLUSIONS: Treatment with empagliflozin for 13 weeks reduced mGFR, estimated ECV and estimated PV in patients with T2D and high risk of cardiovascular events.

OriginalsprogEngelsk
Sider (fra-til)2888-2896
Antal sider9
TidsskriftDiabetes, Obesity and Metabolism
Vol/bind25
Udgave nummer10
Tidlig onlinedato3 jul. 2023
DOI
StatusUdgivet - okt. 2023

Bibliografisk note

© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Fingeraftryk

Udforsk hvilke forskningsemner 'The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes' indeholder.

Citationsformater